We intended to develop a workable inflammation marker in cell-based liquid biopsy to predict malignancy based on a CD44-related circulating rare cell phenotype as an alternative to probe a perhaps more exposed aspect of cancer residual disease. The gene discussed is CD44; the disease is cancer.